Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
Dave Ricks, CEO of pharmaceutical giant Eli Lilly and Co. (NYSE:LLY), delivered a scathing critique of pharmacy benefit managers (PBMs), accusing the industry’s “middle actors” of “rent taking” and creating a “terrible incentive” structure that caused insulin list prices to skyrocket.
Benzinga ·